Portal de Periódicos da CAPES

Uso de resúmenes de evidencia para informar el tratamiento farmacológico de personas con sospecha o diagnóstico de infección respiratoria por SARS CoV-2 / COVID-19

2020; Volume: 7; Issue: 1 Linguagem: Inglês

10.22265/acnef.7.supl.2.407

2500-5006

Nancy Yomayusa González, Eduardo Low Padilla, Ilich Herbert De La Hoz Siegler, Kelly Chacón, Juan Acevedo Peña, Liliana Barrero Garzón, Alexander Barrera, Natalia Tolosa, Andrea Castillo, Freddy Guevara, Diana Castelblanco, Carlos Pinzón Florez, Fredy Mendivelso, Francy Cantor Cruz, Ana C. Gutierrez, Olga Gómez Gómez, Adriana Ávila, Claudia Guevara, Carlos Álvarez, José Rojas Gambasica, Carlos Miguel Arbeláez Duque, Bibiana García Guarín, Martha Cárdenas Rodríguez, Sandra Robayo Rodríguez, Marcela Torres Castro,

COVID-19 Clinical Research Studies

Introduction: Due to the emergence of the SARS-CoV-2 coronavirus since December 2019, a large volume of scientific production has been generated, in some cases uncertain or controversial, especially in the pharmacological management of patients with this infection; therefore, it is considered a relevant search for methodological alternatives to carry out its rigorous, systematic and quality synthesis, but with less execution time and lower cost. Objective: To present the available evidence regarding the pharmacological management of people with suspected or diagnosed respiratory SARS-CoV-2 (COVID-19) using the method of rapid systematic reviews (RS-R) in potentially effective drugs for their management. Methodology: A systematic and structured search was conducted in Medline, Embase, Scopus, Cochrane Library, Clinical trials and Google Scholar in English. Studies included clinical practice guidelines, consensus, systematic reviews, meta-analyses, clinical trials, and other primary studies. Data search and extraction were performed by multiple reviewers, but none were paired. Results: Sixteen questions of clinical interest were resolved, related to the use in COVID-19 of lopinavir/ritonavir, nelfinavir, oseltamivir, remdesivir, ribavirin, teicoplanin, umifenovir, favipiravir, tocilizumab, ivermectin, convalescent plasma; the use of support management drugs such as dexamethasone were also evaluated, as well as the concomitant use of drugs that generated doubts, such as NSAIDs, ACEis, and ARA IIs. Conclusions: Summaries of evidence are within the pandemic scenario as a good methodological alternative to offer quality information in the short term for decision-makers.